Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 35 Breast Neoplasms 34 Lung Neoplasms 20 Triple Negative Breast Neoplasms 6 Neoplasm Metastasis 5 Adenocarcinoma of Lung 5 Uterine Cervical Neoplasms 4 Rhabdomyosarcoma 3 Neoplasms 3 NSCLC 3 Hodgkin Disease 3 Rhabdomyosarcoma, Embryonal 2 Rhabdomyosarcoma, Alveolar 2 Recurrence 2 Adenocarcinoma 2 Thoracic Neoplasms 1 Sarcoma 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Non - Small Cell Lung Cancer NSCLC 1 Neuralgia 1 Metastatic HER2-positive Breast Cancer 1 Mesothelioma, Malignant 1 Malignant mesenchymal tumor 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Lung Diseases 1 HR+HER2- Breast Cancer 1 HER2-positive Advanced Breast Cancer 1

Interventions

Gemcitabine 2 pembrolizumab 1 Vinorelbine 1 Erlotinib Hydrochloride 1 Docetaxel 1 Cisplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Advanced Non-Small Cell Lung Cancer × Vinorelbine × Clear all

NCT00345059 2016-01-14

DISTAL-2

National Cancer Institute, Naples

Phase 3 Terminated

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡